Hamidreza Hashemi

Hamidreza Hashemi has extensive experience in cancer immunotherapy, particularly in the discovery and development of STING agonists for this purpose. With a background in virology and antibody research, Hashemi has worked at various prestigious research institutions and is currently a Senior Scientist at Ambrx, focusing on immune-stimulating antibody conjugates and antibody drug conjugates.